Capital Increase in Genmab as a Result of Employee Warrant

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015

Company Announcement

Copenhagen, Denmark; March 11, 2015 – Genmab A/S (OMX: GEN) will increase its share capital by 1,166,245 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
 

  • 500 shares at DKK 26.75 ,
  • 4,812 shares at DKK 31.75 ,
  • 8,100 shares at DKK 40.41 ,
  • 1,000 shares at DKK 45.24 ,
  • 7,500 shares at DKK 46.74 ,
  • 2,625 shares at DKK 55.85 ,
  • 4,500 shares at DKK 66.60 ,
  • 3,625 shares at DKK 67.50 ,
  • 250 shares at DKK 68.65 ,
  • 7,500 shares at DKK 77 ,
  • 2,375 shares at DKK 79.25 ,
  • 1,500 shares at DKK 80.55 ,
  • 250 shares at DKK 98 ,
  • 12,150 shares at DKK 101 ,
  • 15,325 shares at DKK 114 ,
  • 1,812 shares at DKK 116 ,
  • 8,000 shares at DKK 129.75 ,
  • 3,550 shares at DKK 130 ,
  • 750 shares at DKK 147.50 ,
  • 104,625 shares at DKK 173 ,
  • 47,751 shares at DKK 184 ,
  • 750 shares at DKK 210 ,
  • 3,000 shares at DKK 210.50,
  • 59,594 shares at DKK 224,
  • 5,561 shares at DKK 225.90,
  • 3,025 shares at DKK 231.50,
  • 10,500 shares at DKK 234,
  • 7,500 shares at DKK 234.75 ,
  • 20,385 shares at DKK 246 ,
  • 128,400 shares at DKK 254 ,
  • 202,275 shares at DKK 272 ,
  • 62,350 shares at DKK 326.50 ,
  • 29,155 shares at DKK 329 ,
  • 19,436 shares at DKK 330 ,
  • 271,923 shares at DKK 352.50, and
  • 103,891 shares at DKK 364 .

Proceeds to the company are approx. DKK 317.2 million. The increase corresponds to approx. 2.0 % of the company's share capital.

The increase includes the exercise of 17,500 warrants by board member Anders Gersel Pedersen and the exercise of 15,000 warrants by board member Burton G. Malkiel.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2015. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. Genmab A/S' current share capital amounts to DKK 56,967,419 and will after the capital increase be DKK 58,133,664. The capital increase is expected to be finalized shortly.

The exercise proceeds will increase the company’s cash position accordingly. With the additional proceeds from this warrant exercise we are now projecting an improved cash position at the end of 2015 of DKK 2,600 - 2,700 million. This compares with the previous guidance of DKK 2,300 - 2,400 million. This is the only change to the financial guidance given on March 2, 2015.


About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies.

Company Announcement no. 08
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 141

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 15

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 80

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Africa’s Digital Ownership Debate Gets More Serious

Updated Category News Views 107

Ownership was the uncomfortable word hanging over Cape Town on day two of Africa Tech Festival 2026, and frankly it should make investors sit up. Africa’s digital economy has no shortage of big promises, shiny AI demos or overseas executives talking about opportunity. The harder question is who funds the pipes, owns the data, makes the rules and actually keeps the...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 93

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 61

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 135

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading

Top 5 Most Recently Viewed Articles

Blue Moon Metals Secures C$60 Million for Strategic Growth

Updated Category News Views 164

Blue Moon Metals Announces Major Financing Initiative Blue Moon Metals Inc. (TSXV: MOON; OTCQX: BMOOF), based in Toronto, is embarking on an exciting new phase as the company has entered a letter agreement with key financial partners. These partners include Scotiabank and Canaccord Genuity Corp., who are playing a pivotal role as joint bookrunners in this financial...

Continue Reading
Theravance Biopharma Engages Investors at Upcoming Conference

Updated Category News Views 330

Theravance Biopharma's Upcoming Investor Conference Participation Theravance Biopharma, Inc. (NASDAQ: TBPH) is eager to actively engage with the investment community during a significant event. The company is set to take part in a Fireside Chat at an upcoming health conference, where it will discuss its ongoing projects and recent advancements in its pipeline. This event...

Continue Reading
Bright Green Partners with Benuvia for Raw Material Supply

Updated Category News Views 238

Bright Green Partners with Benuvia Operations Bright Green Corporation (Nasdaq: BGXX) has announced an important partnership through a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leading name in pharmaceutical cannabinoids. This collaboration highlights Bright Green's dedication and capability to...

Continue Reading
EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Osisko Development Unveils Comprehensive Insights on Cariboo Gold

Updated Category News Views 258

Osisko Development Releases Technical Report for Cariboo Gold Project Osisko Development Corp. has taken a significant step in its journey to develop the Cariboo Gold Project by filing a comprehensive technical report. This report, prepared in line with the National Instrument 43-101 guidelines, highlights the feasibility study results for this promising site. The Cariboo...

Continue Reading